SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  For example, here is how to disable FireFox ad content blocking while on Silicon Investor.
Biotech / Medical : Immunomedics (IMMU) - moderated
IMMU 16.72+6.4%Sep 13 12:00 AM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: kdd9998/23/2019 3:20:31 PM
1 Recommendation

Recommended By
ladyPI

   of 52500
 
Link to article on N of 1 trials, not only for already approved drugs, but future trials of new drugs. When done in cloud based setting, this has potential to greatly reduce cost vs RCT trials, plus it can help individual patient determine if a drug works for her. (These are individually blinded trials, but outcome is provided after the trial to each individual. How many of us with chronic diseases have argued with doctor that a medicine does more harm than good for us as individuals, even though it helps a percentage of the population as a whole.) They can statistically collect all the individuals results to determine overall population efficacy.

I think this might be a solution for emab lupus trials (although it still requires the cost of mfg the drugs). When I read this article, I was haunted by the pleas of the woman in our lupus trials who was noticeably helped by emab (she was able to go back to work) but had to go back to a life of misery after the trials ended.

The article says this may be a better way to test orphan drugs where it is hard to enroll enough patients.

the-scientist.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext